690 related articles for article (PubMed ID: 31481583)
1. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract][Full Text] [Related]
2. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.
Gomes Marin JF; Nunes RF; Coutinho AM; Zaniboni EC; Costa LB; Barbosa FG; Queiroz MA; Cerri GG; Buchpiguel CA
Radiographics; 2020 Oct; 40(6):1715-1740. PubMed ID: 33001789
[TBL] [Abstract][Full Text] [Related]
3. Theranostic approaches in nuclear medicine: current status and future prospects.
Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
[No Abstract] [Full Text] [Related]
4. Radioligand Theranostics in the Management of Neuroendocrine Tumors.
Harris AG; Vinik AI; OʼDorisio TM; OʼDorisio MS
Pancreas; 2020; 49(5):599-603. PubMed ID: 32433395
[No Abstract] [Full Text] [Related]
5. An Impressive Approach in Nuclear Medicine: Theranostics.
Vahidfar N; Eppard E; Farzanehfar S; Yordanova A; Fallahpoor M; Ahmadzadehfar H
PET Clin; 2021 Jul; 16(3):327-340. PubMed ID: 34053577
[TBL] [Abstract][Full Text] [Related]
6. Theranostic in Nuclear Medicine - The paradigm of NET.
Giammarile F
Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
[TBL] [Abstract][Full Text] [Related]
7. An introduction to the clinical practice of theranostics in oncology.
Turner JH
Br J Radiol; 2018 Nov; 91(1091):20180440. PubMed ID: 30179054
[TBL] [Abstract][Full Text] [Related]
8. Advances in Radioligand Theranostics in Oncology.
Lawal IO; Abubakar SO; Ndlovu H; Mokoala KMG; More SS; Sathekge MM
Mol Diagn Ther; 2024 May; 28(3):265-289. PubMed ID: 38555542
[TBL] [Abstract][Full Text] [Related]
9. Targeted radionuclide therapy: frontiers in theranostics.
Gallivanone F; Valente M; Savi A; Canevari C; Castiglioni I
Front Biosci (Landmark Ed); 2017 Jun; 22(10):1750-1759. PubMed ID: 28410143
[TBL] [Abstract][Full Text] [Related]
10. Personalized & Precision Medicine in Cancer: A Theranostic Approach.
Choudhury P; Gupta M
Curr Radiopharm; 2017 Nov; 10(3):166-170. PubMed ID: 28758574
[TBL] [Abstract][Full Text] [Related]
11. Theranostic Advances in Breast Cancer in Nuclear Medicine.
Vahidfar N; Aghanejad A; Ahmadzadehfar H; Farzanehfar S; Eppard E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925632
[TBL] [Abstract][Full Text] [Related]
12. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.
Duan H; Iagaru A; Aparici CM
Nanotheranostics; 2022; 6(1):103-117. PubMed ID: 34976584
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic advances of nuclear medicine in oncology].
Valdés Olmos RA; Hoefnagel CA; Bais E; Boot H; Taal B; de Kraker J; Vote PA
Rev Esp Med Nucl; 2001 Dec; 20(7):547-57. PubMed ID: 11709141
[TBL] [Abstract][Full Text] [Related]
14. Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future.
Echavidre W; Fagret D; Faraggi M; Picco V; Montemagno C
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835533
[TBL] [Abstract][Full Text] [Related]
15. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
16. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
17. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
18. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
Werner RA; Weich A; Kircher M; Solnes LB; Javadi MS; Higuchi T; Buck AK; Pomper MG; Rowe SP; Lapa C
Theranostics; 2018; 8(22):6088-6100. PubMed ID: 30613284
[TBL] [Abstract][Full Text] [Related]
19. Radiopeptide imaging and therapy in Europe.
Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR
J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555
[TBL] [Abstract][Full Text] [Related]
20. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
